Novo Nordisk cuts 2026 sales outlook, faces FDA warnings and analyst downgrades as GLP-1 competition and pricing pressures mount.
The Danish pharmaceutical giant Novo Nordisk is navigating a challenging period marked by regulatory scrutiny, revised financial guidance, and a wave of analyst downgrades. This confluence of pressures is testing investor sentiment and raising questions about the stock’s near-term trajectory.
A Diminished Outlook Alarms the Market
Perhaps the most significant development for investors is the company’s forward-looking guidance. For 2026, Novo Nordisk introduced new non-IFRS metrics, projecting an adjusted sales decline of -5% to -13% at constant exchange rates. This outlook excludes a one-time positive effect: the release of $4.2 billion in provisions related to the US 340B drug discount program.
The market reacted negatively to this adjusted perspective, which is intended to reflect the core business trend. Management cited intensifying competition in the GLP?1 drug market—notably from rival Eli Lilly—and pricing pressure from US agreements. A key factor is the “Most-Favored-Nation” pact with the US government, which led to price reductions for Wegovy and Ozempic from November 2025 and set a price for an oral version of Wegovy that was pending at the time.
While the company still anticipates overall GLP?1 market growth and expects to reach more patients, this volume expansion is increasingly likely to be offset by lower realized prices. This is compounded by the impending loss of exclusivity for semaglutid in certain markets. The share price reflects this tension, closing at €33.17 on Friday, remaining well below its moving averages.
Regulatory Warnings Over Marketing Claims
Adding to the company’s challenges, the US Food and Drug Administration (FDA) has issued two warnings in quick succession concerning Novo Nordisk’s consumer advertising. The regulator criticized a promotional spot for the diabetes drug Ozempic, alleging it presented benefits in a manner that was “false or misleading.” This follows a similar warning about a Wegovy advertisement less than a month prior.
The FDA’s specific complaint is that the Ozempic commercial could create the impression that all patients with type?2 diabetes are candidates for every approved use of the drug. In reality, certain advantages apply only to patient subgroups with additional conditions, such as existing cardiovascular or chronic kidney disease. Novo Nordisk must respond within 15 working days, outlining steps to address the issues, which could include revising or discontinuing the advertisements. These actions align with a broader US trend toward stricter oversight of pharmaceutical marketing.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Analyst Community Adjusts Targets Downward
Equity researchers have notably recalibrated their expectations, providing detailed rationales for their changes. Deutsche Bank downgraded the stock to “Hold” from “Buy,” slashing its price target from 400 to 275 DKK, a 31% reduction. The bank highlighted a setback for the drug candidate CagriSema, which failed to demonstrate non-inferiority against Eli Lilly’s Tirzepatid in the REDEFINE?4 Phase?3 trial.
Goldman Sachs maintained a “Neutral” rating but reduced its 12-month price target from $63 to $41, a cut of approximately 35%. The firm pointed to mounting pricing pressure in the GLP?1 business and weaker near-term sales momentum, despite a fourth-quarter earnings per share result of $1.01 beating the consensus estimate of $0.90.
Conversely, Morgan Stanley upgraded its view to “Equal-weight” from “Underweight,” setting a $40 price target. Its analysts argued that the recent sell-off has better priced in medium-term risks, including heavy reliance on semaglutid and the planned halving of Wegovy’s US list price in 2027.
Upcoming Catalysts and Capital Allocation
Key corporate events and clinical milestones remain focal points for investors. At the Annual General Meeting scheduled for 26 March 2026, the board will propose a final dividend of 7.95 DKK per share. This would bring the total expected dividend for 2025 to 11.70 DKK. Furthermore, a new share buyback program of up to 15 billion DKK is planned; its continuation beyond March 2026 is contingent on renewed shareholder approval at the AGM.
Ad
Novo Nordisk Stock: New Analysis – 8 March
Fresh Novo Nordisk information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.
Read our updated Novo Nordisk analysis…
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Aktien-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr.
Jetzt abonnieren.